| ID | 1134 |
| Name of the vaccine | Meningitec |
| Microbe | Bacteria |
| Disease name | Meningococcal disease |
| Name of bacteria | Neisseria meningitidis |
| Type of vaccine | Conjugate |
| Nucleic acid content | DNA |
| Age | Over 2 months |
| Description of the vaccine | Meningococcal serogroup C oligosaccharide conjugate vaccine and contains a protein (called CRM197). |
| Name of the manufacturer | Wyeth Pharmaceuticals |
| Name of the manufacturing country | United Kingdom |
| Year of manufacture | 1999 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-negative diplococcus. |
| Efficacy | Short-term efficacy in infants, children and adolescents. |
| Vaccine formulation | Homogeneous, white suspension |
| Dosage | 0.5 mL injection.
For infants 2 to 12 months: Two doses, at least 2 months apart. |
| Mechanism of action | Make antibodies in the blood. |
| Route of administration | Intramuscular |
| Indications | Protects against infections caused by Neisseria meningitidis type C. |
| Export | Marketing Authorisation Holder: Nuron Biotech B.V., Amsterdam |
| Approval | NA |
| Adjuvant | Aluminium phosphate |
| Repurposing | For meningitis and septicaemia. |
| Side effects of vaccine | In all age groups - swelling, tenderness or pain at the injection site.
In infants and toddlers - loss of appetite, irritability, sleepiness or disturbances of sleeping patterns, being sick, diarrhoea.
In adults – headaches.
In pre-school children – fever. |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | 12675020 |
| Clinical trial number | NA |
| Reference | https://www.hpra.ie/img/uploaded/swedocuments/2125444.PA1886_001_001.40c4897f-403c-4111-9f17-e92f2fae4f8b.000001Product%20Leaflet%20Approved.131106.pdf |
| Other name | NA |
| Additional Links | NA
|